-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Maintains Overweight on Teva Pharmaceutical Indus, Raises Price Target to $42

Benzinga·08/12/2026 12:40:19
Listen to the news
Barclays analyst Glen Santangelo maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Overweight and raises the price target from $40 to $42.